My inbox was burning-up with emails from readers who had just read about ImMucin, a new anti-cancer vaccine that is expected to work well against a number of different cancers.
It just so happens the first human tests by Israeli researchers were conducted on multiple myeloma patients. And the results were everything researchers had hoped for!
According to Medical Daily:
“The clinical trial was conducted at the Hadassah Medical Centre in Jerusalem and consisted of ten patients with multiple myeloma, a type of blood cancer that affects plasma cells in bone marrow, have now received the vaccine.
Researchers from the drug maker Vaxil Biotheraputics and Tel Aviv University said that seven of the patients who have finished treatment all had significantly greater immunity against cancer cells compared to before they were given the vaccine, and three of the patients in the study are now free of the condition. “
ImMucin targets a molecule which is present in most cancers. I first wrote about it in June on my MyelomaNews.com site. Come on, people. Weren’t you paying attention? Here is a link back to the June, 2011 post:
A number of different publications are running stories about ImMucin now. Preliminary study results haven’t even been published yet. But the age-old trick of letting news about the study trickle-out ahead of time has really worked this time! CLICK HERE to access yesterday’s Medical Daily article that I quoted above.
As it so happens, this is only one of two exciting cancer therapy studies making the news this week. I will share details about the other one tomorrow.
Feel good and keep smiling! Pat